Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Rhea-AI Summary
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that Jack A. Khattar, President and CEO, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on May 12, 2026 at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas.
Investors may request meetings through the Bank of America coordinator. A live audio webcast and a 60-day archived replay will be available via the company’s Investor Relations Events & Presentations page at www.supernus.com/Investors.
Positive
- None.
Negative
- None.
News Market Reaction – SUPN
In the May 7 session, SUPN gained 1.61%, reflecting a mild positive market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Earnings date notice | Neutral | +0.2% | Announced Q1 2026 results release date and earnings call logistics. |
| Apr 20 | Board change (peer) | Positive | -4.2% | Alpha Cognition added an experienced director supporting ZUNVEYL launch plans. |
| Feb 24 | Earnings results | Positive | +5.7% | Reported record Q4 and FY 2025 revenues and provided 2026 guidance. |
| Feb 23 | Investor conferences | Neutral | +5.2% | Outlined participation in several March 2026 investor conferences and webcasts. |
| Feb 12 | Earnings date notice | Neutral | +2.0% | Set date and time to report Q4 and full-year 2025 financial results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
SUPN has generally reacted positively to operational and investor-relations updates, with only one recent divergence around peer-focused board news.
Over the last six months, Supernus has combined strong fundamentals with active investor outreach. Record Q4 and full-year 2025 results on Feb 24 coincided with a 5.67% gain. Investor conference participation announced on Feb 23 saw shares rise 5.15%. Earnings-date notices on Feb 12 and Apr 22 produced smaller positive moves. The lone negative reaction followed an April 20 peer board-change announcement. Today’s Bank of America conference appearance continues this pattern of frequent conference engagement.
Key Terms
central nervous system (cns) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.
Investors interested in arranging a meeting with company management during the conference should contact the Bank of America conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section of the Supernus Pharmaceuticals website at www.supernus.com/Investors. An archived replay of the webcasts will be available for 60 days on the Company's website following the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; the Company's ability to increase its net revenue from its products, and the products of its subsidiaries; the Company's ability to commercialize its products, and the products of its subsidiaries; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
